Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2006; 12(21): 3386-3392
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3386
Published online Jun 7, 2006. doi: 10.3748/wjg.v12.i21.3386
Table 2 Disease activity index, UC patients
| t/d | All | Responder | Non-responder | Operated( |
| (n = 22) | (n = 10) | (n = 12) | n = 5) | |
| 1 | 9.4 (5-12) | 9.5 (5-12) | 9.4 (5-12) | 11.2 (10-12) |
| 3 | 7.4 (2-12) | 7.1 (2-10) | 7.6 (5-12) | 12 |
| 7 | 5.7 (2-9) | 4.8 (2-7) | 7.2 (5-9) | NA |
| 28 | 2.5 (0-8) | 0.8 (0-2) | 5 (3-8) | NA |
-
Citation: Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellström PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders
versus nonresponders. World J Gastroenterol 2006; 12(21): 3386-3392 - URL: https://www.wjgnet.com/1007-9327/full/v12/i21/3386.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i21.3386